Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2026-01-01 @ 10:35 AM
Study NCT ID:
NCT05179668
Status:
UNKNOWN
Last Update Posted:
2022-10-25
First Post:
2021-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SGLT2 Inhibition in Hemodialysis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D051437', 'term': 'Renal Insufficiency'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D051436', 'term': 'Renal Insufficiency, Chronic'}, {'id': 'D017379', 'term': 'Hypertrophy, Left Ventricular'}], 'ancestors': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D006332', 'term': 'Cardiomegaly'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D006984', 'term': 'Hypertrophy'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C529054', 'term': 'dapagliflozin'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 108}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-10-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-10', 'completionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-10-21', 'studyFirstSubmitDate': '2021-12-16', 'studyFirstSubmitQcDate': '2021-12-16', 'lastUpdatePostDateStruct': {'date': '2022-10-25', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-01-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-04-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Δ Left ventricular mass indexed to body surface area', 'timeFrame': 'From baseline to 6 months', 'description': 'measured by cMRI'}], 'secondaryOutcomes': [{'measure': 'Δ HbA1c [%]', 'timeFrame': 'From baseline to 6 months', 'description': 'Change in relative %'}, {'measure': 'Δ Left ventricular mass indexed to body height', 'timeFrame': 'From baseline to 6 months', 'description': 'measured by cMRI'}, {'measure': 'Δ Left ventricular ejection fraction', 'timeFrame': 'From baseline to 6 months', 'description': 'measured by cMRI'}, {'measure': 'Δ Cardiac fibrosis', 'timeFrame': 'From baseline to 6 months', 'description': 'measured by cMRI'}, {'measure': 'Δ Body weight [kg]', 'timeFrame': 'From baseline to 6 months', 'description': 'Change in kg'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Dapagliflozin', 'SGLT2 inhibition'], 'conditions': ['Kidney Failure', 'Hemodialysis', 'Diabetes Mellitus, Type 2', 'Chronic Kidney Disease', 'Left Ventricular Hypertrophy']}, 'descriptionModule': {'briefSummary': 'The study is designed as a prospective randomized, controlled, double-blinded phase II trial to examine the effect of the SGLT2 inhibitor dapagliflozin, in comparison with placebo on cardiovascular outcome parameters in kidney failure patients undergoing replacement therapy with hemodialysis.\n\nThe primary endpoint is the change (∆) in left ventricular mass indexed to body surface area (LVMi) from baseline to 6 months measured by cardiac magnetic resonance imaging.\n\nNull and alternative hypotheses:\n\nH0: There is no difference in the ∆ Left Ventricular Mass indexed to BSA after six months of treatment, comparing patients having received the SGLT2-Inhibitor Dapagliflozin versus placebo.\n\nH1: There is a difference in the ∆ Left Ventricular Mass indexed to BSA comparing patients having received the SGLT2-Inhibitor Dapagliflozin versus placebo.', 'detailedDescription': 'The parallel groups will receive dapagliflozin 10 mg vs. placebo (1:1 manner; n = 54 per group) for 6 months. Cardiological outcome parameters will include the change in left ventricular mass (LVM), left ventricular ejection fraction (EF), cardiac fibrosis and left atrial diameter (LAD) from baseline to 6 months measured by cMRI and strain echocardiography.\n\nBiochemical data will be collected prior to hemodialysis at baseline and periodically (e.g. blood gas analysis at every dialysis visit, measurements of and pre- and post- dialysis troponin T (TnT) and pro brain natriuretic peptide (proBNP) every 4 weeks).\n\nA full laboratory analysis of blood cell count, blood coagulation and clinical chemistry will be performed at baseline, 3 months, and 6 months. Additionally, body weight will be measured at all study visits to monitor changes after SGLT2 inhibitor administration. Hospitalizations and mortality will be monitored clinically.\n\nFurther secondary endpoints are glucometabolic parameters (HbA1c, plasma values of insulin, c-peptide, glucagon, glucagon-Like peptide-1 (GLP1), cortisol, growth hormone, alanine, β-hydroxybutyrate (βOHB) \\[=ketone\\] and pyruvate concentration) and will be determined at baseline, 3 and 6 months. The HOMA-Indices will be calculated with the values of insulin and fasting glucose for monitoring of diabetes performed at baseline, 3 months, and 6 months.\n\nVolume status and fluid composition will be measured by bioimpedance spectroscopy at the baseline, 3 months, and end-of-study-visit. In case of hypervolemia, ultrafiltration parameters will be adapted to reach a dry weight based in synopsis of clinical status and body composition monitoring results.\n\nIn terms of urinary output and tubuloglomerular feedback, a stratification by residual urine volume by 200 mL per day will be performed to elucidate study aim IV. Prior results of diabetes independent renal and cardiovascular benefit legitimate an examination of groups with and without prevalent diabetes mellitus.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age ≥18 years\n* Maintenance hemodialysis 3×/week for ≥3 months and ≤3 years\n* BMI \\<45 kg/m2 and stable weight (± 5 kg \\["dry weight"\\]) over the preceding three months\n* Signed informed consent\n\nExclusion Criteria:\n\nStudy specific:\n\n* Contraindications for MRI\n* Hypersensitivity or Intolerance of SGLT2 inhibitors\n* Participation in another clinical trial\n\nMedical condition specific:\n\n* History of diabetic ketoacidosis\n* Interventricular septum width ≤ 11 mm\n* Severe valvular heart disease\n* Life expectancy \\< 1 year\n* Substance abuse\n* History of Type 1 diabetes mellitus\n* Scheduled kidney transplant from a living donor\n* Other significant disease or pathology, that might predispose that patient to an unacceptable risk or interferes with the study in the opinion of the investigator.\n* Acute coronary syndrome during the last 30 days\n* Existing treatments with SGLT2i within the last 6 months\n\nFemale specific:\n\n* Child bearing potential \\& unwilling / unable to use an acceptable method to avoid pregnancy for the entire study (estrogen and/or progesterone treatment).\n* Pregnancy\n* Breast feeding'}, 'identificationModule': {'nctId': 'NCT05179668', 'acronym': 'DAPA-HD', 'briefTitle': 'SGLT2 Inhibition in Hemodialysis', 'organization': {'class': 'OTHER', 'fullName': 'Medical University of Vienna'}, 'officialTitle': 'SGLT2 Inhibition (Dapagliflozin) in Diabetic and Non-diabetic Hemodialysis Patients With and Without Residual Urine Volume: a Prospective Randomized, Placebo-controlled, Double-blinded Phase II Trial', 'orgStudyIdInfo': {'id': 'EK-Nr.: 1196/2021'}, 'secondaryIdInfos': [{'id': '2021-000733-14', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Intervention arm', 'description': 'Hemodialysis patients receiving dapagliflozin 10 mg once daily', 'interventionNames': ['Drug: Dapagliflozin 10 MG']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Hemodialysis patients receiving placebo oral tablet once daily', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Dapagliflozin 10 MG', 'type': 'DRUG', 'otherNames': ['Forxiga 10 MG'], 'description': 'administered orally once daily', 'armGroupLabels': ['Intervention arm']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'administered orally once daily', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '1090', 'city': 'Vienna', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Christopher Paschen', 'role': 'CONTACT', 'email': 'christopher.paschen@meduniwien.ac.at'}, {'name': 'Manfred Hecking', 'role': 'CONTACT', 'email': 'manfred.hecking@meduniwien.ac.at'}], 'facility': 'Medical University of Vienna', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}], 'centralContacts': [{'name': 'Christopher Paschen, MD', 'role': 'CONTACT', 'email': 'christopher.paschen@meduniwien.ac.at', 'phone': '014040043910'}, {'name': 'Manfred Hecking, MD, PhD', 'role': 'CONTACT', 'email': 'manfred.hecking@meduniwien.ac.at', 'phone': '014040043910'}], 'overallOfficials': [{'name': 'Manfred Hecking, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Medical University of Vienna, Department of Medicine III, Division of Nephrology and Dialysis'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Medical University of Vienna', 'class': 'OTHER'}, 'collaborators': [{'name': 'Vienna Dialysis Center', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Assoc. Prof. Dr. Manfred Hecking, MD PhD', 'investigatorAffiliation': 'Medical University of Vienna'}}}}